Nav1.6 (encoded by SCN8A) is targeted by commonly used sodium channel-blocking drugs, the most efficacious ASMs for people with monogenic SCN8A-related epilepsies, that are often caused by gain-of-function pathogenic variants45. Here, SCN8A is linked to epilepsy.